Acurx Pharmaceuticals, Inc.
NASDAQ:ACXP
0.7199 (USD) • At close January 15, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 1.198 | 1.826 | 1.555 | 1.943 | 1.349 | 1.736 | 1.016 | 1.433 | 1.591 | 0.912 | 0.819 | 0.716 | 1.127 | 0.095 | 0.092 | 0.458 | 0.66 | 0.401 | 0.685 |
| General & Administrative Expenses
| 1.623 | 2.296 | 2.823 | 3.172 | 1.766 | 1.709 | 1.887 | 1.828 | 1.951 | 1.709 | 1.851 | 1.911 | 3.515 | 3.975 | 1.382 | 0.635 | 0.655 | 0.513 | 0.594 |
| Selling & Marketing Expenses
| 0 | 0 | -2,820.055 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 1.623 | 2.296 | 2.823 | 3.172 | 1.766 | 1.709 | 1.887 | 1.828 | 1.951 | 1.709 | 1.851 | 1.911 | 3.515 | 3.975 | 1.382 | 0.635 | 0.655 | 0.513 | 0.594 |
| Other Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses
| 2.822 | 4.122 | 4.378 | 5.115 | 3.115 | 3.445 | 2.903 | 3.261 | 3.542 | 2.621 | 2.67 | 2.627 | 4.642 | 4.071 | 1.474 | 1.093 | 1.315 | 0.913 | 1.279 |
| Operating Income
| -2.822 | -4.122 | -4.378 | -5.115 | -3.115 | -3,445.24 | -2.903 | -8.552 | -3.542 | -2.621 | -2.67 | -2.627 | -4.642 | -4.071 | -1.474 | -1.093 | -1.315 | -0.913 | -1.279 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.067 | 0 | 0 | 0 | 0 | 0 |
| Income Before Tax
| -2.822 | -4.122 | -4.378 | -5.115 | -3.115 | -3.445 | -2.903 | -3.261 | -3.542 | -2.621 | -2.67 | -2.627 | -4.642 | -4.004 | -1.474 | -1.093 | -1.315 | -0.913 | -1.279 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0 | 0 | -4.378 | -0.005 | -0.003 | 3,441.673 | -0.003 | -5.292 | -0.004 | -0.003 | -2.67 | 5.203 | -4.642 | -0.067 | -1.474 | -1.093 | -1.315 | -0.913 | -1.279 |
| Net Income
| -2,821.597 | -4.122 | -4.378 | -5.115 | -3.115 | -3.445 | -2.903 | 2.031 | -3.542 | -2.621 | -2.67 | -2.627 | -4.642 | -4.004 | -1.474 | -1.093 | -1.315 | -0.913 | -1.279 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -0.17 | -0.26 | -0.28 | -0.38 | -0.24 | -0.28 | -0.25 | 0.18 | -0.32 | -0.26 | -0.26 | -0.38 | -0.46 | -0.57 | -0.15 | -0.11 | -0.14 | -0.096 | -0.13 |
| EPS Diluted
| -0.17 | -0.26 | -0.28 | -0.38 | -0.24 | -0.28 | -0.25 | 0.18 | -0.32 | -0.26 | -0.26 | -0.38 | -0.46 | -0.57 | -0.15 | -0.11 | -0.14 | -0.096 | -0.13 |
| EBITDA
| -2.822 | 0 | 0 | -5.115 | -3.115 | -3.445 | -2.903 | -3.261 | -3.542 | -2.621 | -2.67 | -2.627 | -4.642 | 0 | -1.474 | 0 | 0 | -0.913 | -1.279 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |